Skip to main content
Close

Sarcoma

Protocols

Adult Soft Tissue Sarcoma

SAAI

Therapy for Advanced Soft Tissue Sarcoma Using DOXOrubicin, Ifosfamide-Mesna


SAAJA

DOXOrubicin for Adjuvant Use for Patients with Non-Metastatic Operable Large High Grade Soft Tissue Sarcoma 


SAAJADIC

Adjuvant Treatment of Patients with Soft Tissue Sarcoma using DOXOrubicin and Dacarbazine


SAAVA

Therapy for Advanced Soft Tissue Sarcoma Using DOXOrubicin


SAAVGEMD

Therapy for Soft Tissue Sarcomas Using Gemcitabine and DOCEtaxel


SAAVI

Therapy for Advanced Soft Tissue Sarcoma Using Ifosfamide


SAAVADIC

Treatment of Patients with Soft Tissue Sarcoma Using DOXOrubicin and Dacarbazine


SADTIC

High Dose Single Agent Dacarbazine (DTIC) for Metastatic Soft Tissue Sarcoma


SAHIPEC

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients with Peritoneal Desmoplastic Small Round Cell Tumour (DSRCT) Using CISplatin

USATEMBEV

Therapy for Advanced Solitary Fibrous Tumours and Hemangiopericytoma Using Temozolomide and Bevacizumab

SAVDC

Adjuvant Therapy for Rhabdomyosarcoma Using vinCRIStine, Dactinomycin, and Cyclophosphamide

SAVDCM

Adjuvant Therapy for Rhabdomyosarcoma Using vinCRIstine, Dactinomycin, Cyclophosphamide and Mesna

Gastrointestinal Stromal Cell Tumours (GIST)

SAAJGI

Adjuvant Treatment of C-Kit Positive High Risk Gastrointestinal Stromal Cell Tumours Using Imatinib


SAAVGI

Treatment of Advanced c-Kit Positive and c-Kit Negative Gastrointestinal Stromal Cell Tumors (GIST's) Using Imatinib


SAAVGIDD

Treatment of Advanced c-Kit Positive Gastrointestinal Stromal Cell Tumors (GIST's) Using 800 mg Dosing of imatinib


USAAVGR

Third Line Treatment of Advanced Gastrointestinal Stromal Cell Tumours (GIST's) Using Regorafenib


SAAVGS

Second Line Treatment of Advanced C-Kit Positive Gastrointestinal Stromal Cell Tumours (GIST's) After Imatinib Using Sunitinib

Osteosarcoma

SAAJAP

Adjuvant Therapy for Osteosarcoma Using DOXOrubicin and CISplatin


SAAVAP

Therapy of Advanced Osteosarcoma Using DOXOrubicin and CISplatin  


SAHDMTX

Treatment of Osteosarcoma Using High Dose Methotrexate with Leucovorin Rescue


USANADENO

Denosumab for Neoadjuvant Use in Patients with Non-Metastatic Operable Giant Cell Tumour of the Bone

Fibromatosis

SAMV

Palliative Therapy for Aggressive Fibromatosis Using Weekly or Alternate Week Methotrexate and vinBLAstine Intravenously


SATAM

Therapy for Recurrent Desmoid Tumors/Aggressive Fibromatosis Using Tamoxifen

Pediatric Sarcomas & Post-Pediatric Disease

SAALT2W

Etoposide, Ifosfamide-Mesna (SAIME) Alternating with vinCRIStine, DOXOrubicin and Cyclophosphamide (with or without Mesna)(SAVAC or SAVACM) with Filgrastim Support at a TWO Weekly Intervals for Newly Diagnosed Ewing's Sarcoma/ Ewing’s Family of Tumours, Desmoplastic Intra-abdominal Small Round Blue Cell tumour or Rhabdomyosarcoma


SAALT3W

Etoposide, Ifosfamide-Mesna (SAIME) Alternating with vinCRIStine, DOXOrubicin and Cyclophosphamide (with or without Mesna)(SAVAC or SAVACM) with Filgrastim Support at a THREE Weekly Intervals for Newly Diagnosed Ewing's Sarcoma/ Ewing’s Family of Tumours, Desmoplastic Intra-abdominal Small Round Blue Cell tumour or Rhabdomyosarcoma


SAAVIME3

3-Day Etoposide & Ifosfamide-Mesna for Patients with Advanced Soft Tissue or Bony Sarcomas


SAAVTC

Treatment of Recurrent/refractory Neuroblastoma, Ewing's Sarcoma, Osteogenic Sarcoma or Rhabdomyosarcoma with Topotecan/Cyclophosphamide


SAIME

Etoposide, Ifosfamide-Mesna for Patients with Newly Diagnosed Ewing's Sarcoma/Peripheral Neuroectodermal Tumor (PNET) or Rhabdomyosarcoma or Advanced Soft Tissue or Bony Sarcomas


SAVAC

Treatment of Sarcomas with vinCRIStine, DOXOrubicin and Cyclophosphamide (SAVAC) 


SAVACM

Treatment of Sarcomas with Pelvic Primaries or Chemotherapy Induced Hematuria Using vinCRIStine, DOXOrubicin, Cyclophosphamide and Mesna

Terms of use

The information contained in these documents is a statement of consensus of BC Cancer Agency professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. 

Use of these documents is at your own risk and is subject to the BC Cancer Agency's Terms of Use.
Tab Heading
Tab Heading
SOURCE: Sarcoma ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Cancer Agency. All Rights Reserved.

    Copyright © 2017 Provincial Health Services Authority